Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: Subanalysis of a parallel group, open-label, dose-escalation study

Clinical Neuropharmacology

Volumn 29, Issue 4, 2006, Pages 238-242

  Babic, Tomislav ^a   Boothmann, Bernard ^b   Polivka, Jiri ^c   Rektor, Ivan ^d   Boroojerdi, Babak ^e   Häck, Hermann Josef ^e   Randerath, Olaf ^e  

^a I3 Research   (United Kingdom)

^b BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

^c Faculty Hospital   (Czech Republic)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^e Schwarz Pharma AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; ECG ABNORMALITY; FEMALE; HALLUCINATION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SOMNOLENCE; TITRIMETRY; VOMITING; DOSE RESPONSE; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, CUTANEOUS; AGED; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 33748753171     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000228179.83335.65     Document Type: Article

References (6)

1. Behrens S, Sommerville K. Non-oral drug delivery in Parkinson's disease: a summary from the symposium at the 7th International Congress of Parkinson's Disease and Movement Disorders. 10-14 November 2002, Miami, FL, USA. Expert Opin Pharmacother April 2003;4(4):595-599.
2. Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson Disease. Curr Med Res Opin. 18(4):209-214.
3. Metman LV, Gillespie M, Farmer C, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson disease. Clin Neuropharmacol May 2001-June 2001;24(3):163-169.
4. Parkinson Study Group (PSG). A controlled trial of rotigotine monotherapy in early Parkinson disease. Arch Neurol Dec 2003;60(12):1721-1728.
5. Pfeiffer RF. Potential of transdermal drug delivery in Parkinson disease. Drugs Aging 2002;19(8):561-570.
6. Watts RL, LeWitt PA, Sommerville KW, et al. Rotigotine transdermal patch (Neupro ®) is efficacious and safe in patients with early-stage, idiopathic Parkinson disease, regardless of gender, age, duration and severity of disease. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Mov Disord 2005;20(Suppl 10):S93.